Key result
Surgery plus doxorubicin and ifosfamide achieves 24-month recurrence-free survival in a left atrial leiomyosarcoma case.
Why the study?
Does surgery and adjuvant chemotherapy improve survival in a patient with primary left atrium leiomyosarcoma?
Case Report (n=1)
No
Does surgery and adjuvant chemotherapy improve survival in a patient with primary left atrium leiomyosarcoma?
This case report demonstrates a 24-month recurrence-free survival in a patient with rare primary cardiac leiomyosarcoma treated with surgery and adjuvant chemotherapy.
Answers are grounded in this paper and cite their sources.
May support surgery plus adjuvant chemotherapy in primary cardiac leiomyosarcoma; leaves open confirmation of survival benefit.
BACKGROUND: Cardiac tumors are a very rare entity. Leiomyosarcoma represents less than 1% of cases. CASE PRESENTATION: a 51-year-old woman diagnosed with primary left atrium leiomyosarcoma. She was treated by optimal surgery and adjuvant chemotherapy. She is still alive after a follow-up of 24 months without evidence of local or distant recurrence. CONCLUSIONS: Cardiac leiomyosarcoma is a rare tumor with a dismal prognosis. Surgery is the mainstay of treatment. Adjuvant treatment is still controversial.
No takes yet. Share an insight, caveat, or question.
Béhi et al. (2017) conducted a case report in Primary cardiac leiomyosarcoma (n=1). Surgery and adjuvant chemotherapy (Doxorubicin and Ifosfamide) was evaluated on Survival without recurrence. A 51-year-old woman with primary left atrium leiomyosarcoma treated with surgical excision and adjuvant doxorubicin and ifosfamide remained alive without recurrence after 24 months of follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: